SEC Form 4 · accession 0001562180-18-004807
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Olivier Danos
Officer — Chief Scientific Officer
Period of report
Nov 30, 2018
Accepted (ET)
Dec 4, 2018 · 4:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 30, 2018 | M | 1,500 | $20.35 | A | 1,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $20.35 | Nov 30, 2018 | M | 1,500 | D | — | Mar 26, 2027 | Common Stock | 1,500 | 78,500 | D |
Explanation of responses
- F1The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.